Olipudase alfa (2) – Xenpozyme®
Acid sphingomyelinase deficiency (ASMD) type A/B or type B
Characteristics
| Start date | 01.05.2026 |
|---|---|
| Resolution | 15.10.2026 – active procedure |
| INN | Olipudase alfa |
| Brand name | Xenpozyme® |
| Pharm. company | Sanofi-Aventis Deutschland GmbH |
| G-BA Procedure ID | D-1316 |
| Therapeutic area | Metabolic diseases Orphan (turnover limit) |
| Reason for procedure | Reassessment: Orphan turnover exceeded |
Associated procedures
| Olipudase alfa (2) | Xenpozyme® | Sanofi-Aventis Deutschland GmbH | Acid sphingomyelinase deficiency (ASMD) type A/B or type B | n.d. | active procedure Orphan (turnover limit) | |
| Olipudase alfa (1) | Xenpozyme® | Sanofi-Aventis Deutschland GmbH | Acid sphingomyelinase deficiency (ASMD) type A/B or type B | 70–80 | 100% Hint for non-quantifiable additional benefit Orphan |
<< List of all resolutions